Paula Pohlmann, Professor at The University of Texas M.D. Anderson Cancer Center, shared a post on LinkedIn:
“At SABCS 2025, led by Dr Valero, our team presented new real‑world data on clinical outcomes of T‑DM1 following T‑DXd in metastatic breast cancer (mBC). In this small cohort, median PFS was 2.1 months, suggesting that T‑DM1 provides modest benefit in the post‑T‑DXd setting.
These findings will need to be confirmed in larger cohorts.The results underscore a critical reality: patients progressing after T‑DXd face a significant therapeutic gap, highlighting the urgent need for more effective options in mBC.”
More posts featuring Paula Pohlmann on OncoDaily.